Efficacy and Safety in Hepatitis C Recurrence Therapy
PROTECT. Pegylated Interferon alfa-2b and Ribavirin After Orthotopic Liver Transplantation: Efficacy and Safety in Hepatitis C Recurrence Therapy
The primary endpoint for this study will be to determine the sustained virologic response (SVR) at the 24-week follow up after treatment with PEG-IFN -2b and Ribavirin in post-orthotopic liver transplant (OLT) recipients with recurrent HCV.
Patients whom have had a liver transplant for end stage liver disease due to recurrent HCV.
Integrated Therapeutics/ Schering Plough
Karen Matijevich, RN